122 related articles for article (PubMed ID: 32292577)
41. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
[TBL] [Abstract][Full Text] [Related]
42. Correction: Calcium electroporation for treatment of sarcoma in preclinical studies.
Szewczyk A; Gehl J; Daczewska M; Saczko J; Frandsen SK; Kulbacka J
Oncotarget; 2019 Aug; 10(49):5118. PubMed ID: 31489120
[TBL] [Abstract][Full Text] [Related]
43. Correction: Proteomic screening identifies the zonula occludens protein ZO-1 as a new partner for ADAM12 in invadopodia-like structures.
Dekky B; Ruff M; Bonnier D; Legagneux V; Théret N
Oncotarget; 2018 Nov; 9(87):35795. PubMed ID: 30515271
[TBL] [Abstract][Full Text] [Related]
44. A current and comprehensive review of cyclin-dependent kinase inhibitors for the treatment of metastatic breast cancer.
Bilgin B; Sendur MAN; Şener Dede D; Akıncı MB; Yalçın B
Curr Med Res Opin; 2017 Sep; 33(9):1559-1569. PubMed ID: 28657360
[TBL] [Abstract][Full Text] [Related]
45. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
46. Correction: Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer.
Brüstle K; Heidecker B
Oncotarget; 2018 Sep; 9(70):33440. PubMed ID: 30279972
[TBL] [Abstract][Full Text] [Related]
47. Correction: Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.
Bekker P; Dairaghi D; Seitz L; Leleti M; Wang Y; Ertl L; Baumgart T; Shugarts S; Lohr L; Dang T; Miao S; Zeng Y; Fan P; Zhang P; Johnson D; Powers J; Jaen J; Charo I; Schall TJ
PLoS One; 2019; 14(1):e0210593. PubMed ID: 30608991
[TBL] [Abstract][Full Text] [Related]
48. Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix.
Mann M; Kumar S; Chauhan SS; Bhatla N; Kumar S; Bakhshi S; Gupta R; Sharma A; Kumar L
Oncotarget; 2019 Jul; 10(46):4802. PubMed ID: 31413820
[TBL] [Abstract][Full Text] [Related]
49. FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer.
Shah A; Bloomquist E; Tang S; Fu W; Bi Y; Liu Q; Yu J; Zhao P; Palmby TR; Goldberg KB; Chang CJG; Patel P; Alebachew E; Tilley A; Pierce WF; Ibrahim A; Blumenthal GM; Sridhara R; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Jul; 24(13):2999-3004. PubMed ID: 29437768
[TBL] [Abstract][Full Text] [Related]
50. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
51. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy.
Robb CM; Kour S; Contreras JI; Agarwal E; Barger CJ; Rana S; Sonawane Y; Neilsen BK; Taylor M; Kizhake S; Thakare RN; Chowdhury S; Wang J; Black JD; Hollingsworth MA; Brattain MG; Natarajan A
Oncotarget; 2020 Jun; 11(25):2462-2463. PubMed ID: 32637035
[TBL] [Abstract][Full Text] [Related]
52. Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
Hideshima T; Mazitschek R; Qi J; Mimura N; Tseng JC; Kung AL; Bradner JE; Anderson KC
Oncotarget; 2021 Aug; 12(17):1736. PubMed ID: 34434504
[TBL] [Abstract][Full Text] [Related]
53. Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer.
Hu Y; Yu T; Liu X; He Y; Deng L; Guo J; Hua Y; Luo T; Gao X
Oncotarget; 2020 Sep; 11(37):3484-3485. PubMed ID: 32973972
[TBL] [Abstract][Full Text] [Related]
54. Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Caroline R; Sofia G; Catherine P; Remi B; Pierre C; Olivier B; Laurent G; Valentin A; Claude C; Odile F
Oncotarget; 2019 Mar; 10(22):2236. PubMed ID: 31040915
[TBL] [Abstract][Full Text] [Related]
55. Correction: The combination of early treatment response and ypT stage is a novel metric to stage rectal cancer patients treated with neoadjuvant chemoradiotherapy.
Cui J; Yang L; Guo L; Shao Y; Tan D; Li N; Zhang H
Oncotarget; 2019 Feb; 10(15):1539. PubMed ID: 30863500
[TBL] [Abstract][Full Text] [Related]
56. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
Cersosimo RJ
Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
[TBL] [Abstract][Full Text] [Related]
57. Correction:
Holien T; Misund K; Olsen OE; Baranowska KA; Buene G; Børset M; Waage A; Sundan A
Oncotarget; 2018 Nov; 9(89):36048. PubMed ID: 30542518
[TBL] [Abstract][Full Text] [Related]
58. Correction: Discovery of a FLT3 inhibitor LDD1937 as an anti-leukemic agent for acute myeloid leukemia.
Lee HJ; Lee J; Jeong P; Choi J; Baek J; Ahn SL; Moon Y; Heo JD; Choi YH; Chin YW; Kim YC; Han SY
Oncotarget; 2018 Apr; 9(28):20219. PubMed ID: 29733074
[TBL] [Abstract][Full Text] [Related]
59. Correction: Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor.
Hu Z; Hu Y; Liu X; Xi R; Zhang A; Liu D; Xie Q; Chen L
Oncotarget; 2018 Oct; 9(81):35283. PubMed ID: 30443295
[TBL] [Abstract][Full Text] [Related]
60. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
